Spanish CDMO 3P Biopharmaceuticals inks manufacturing deal with Intervacc

horse swimming in water
Spanish CDMO 3P Biopharmaceuticals inked a deal to produce the Strangvac equine vaccine to treat strangles. (Callipso/iStock/Getty Images Plus/Getty Images)

3P Biopharmaceuticals, a Spanish CDMO, has inked a deal with Sweden's Intervacc to produce the company’s Strangvac equine vaccine to treat strangles.

Financial terms of the agreement weren’t disclosed.

Strangles is caused by Streptococcus equi in horses and is highly contagious. It can cause severe infection leading to significant suffering and economic loss for the global equine industry, the company said. The vaccine is the first candidate in the pipeline of a new generation of such drugs that are being developed with recombinant proteins.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“This is an important milestone in the process to complete the registration of Strangvac® and especially considering that there is a huge need for a safe and efficacious vaccine against equine strangles as evidenced by all current reported outbreaks around the world,” Jan-Ingmar Flock, Intervacc’s chief executive, said in a statement.

The agreement covers transfer of the manufacturing technology, production of validation batches and long-term future commercial manufacturing.

Read more on

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.